Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
March 1993
Revised Date: 
Feb 2024
  • Blood pressure support
  • Treatment of cardiac decompensation in Persistent Pulmonary Hypertension of the Newborn
  • IV continuous infusion

Usual dosing range: 2.5- 10 mcg/kg/minute; maximum 20 mcg/kg/min

Side Effects: 
  • CVS: tachycardia, arrhythmias, hypertension
  • Local: tissue sloughing/necrosis with extravasation-consider treating with phentolamine 0.5 mg/mL solution
Parameters to Monitor: 
  • HR
  • BP
  • ECG
  • Urine output
  • Injection site
Reconstitution and Stability: 
  • DOBUTamine 12.5 mg/mL:
    • Take 1.28 mL (16 mg) and add to 18.72 mL D5W
    • Final concentration: 800 mcg/mL
  • DOBUTamine 12.5 mg/mL:
    • Take 2.56 mL (32 mg) and add to 17.44 mL D5W
    • Final concentration: 1600 mcg/mL

- Solutions Compatible:  dextrose up to D10W, 0.9% NaCl, dextrose-saline combinations


- Y-site Compatible: dopamine, epinephrine, fentanyl, KCl, morphine, SMOF, TPN


- Incompatible: acyclovir, alteplase, furosemide, heparin, insulin, midazolam, sodium bicarbonate


  • Pink discolouration indicates oxidation, but no potency loss over 24 hours

- Taketomo CK, Hodding JH, Kraus DM.  Pediatric Dosage Handbook 19th edition. Hudson: Lexi-Comp Inc.; 2012

- Trissel LA. Handbook on Injectable Drugs. 16th Edition. Bethesda: American Society of Health-System Pharmacists 2011

- Evidence-based Practice for Improving Quality  (EPIQ) Recommendations on Hemodynamics, 2023

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.